DelveInsight

DelveInsight, a prominent business consulting and market research firm, distinguishes itself by seamlessly merging industry expertise with insightful market analysis methodologies to furnish crucial insights to top-tier decision-makers. The organization's mission centers around assisting its clientele in the acquisition of pertinent information, thereby enhancing their decision-making capabilities. DelveInsight is adept at recognizing potential market opportunities, conducting competitor assessments, and undertaking comprehensive evaluations of the business environment. Notably, DelveInsight serves as a trusted and informed partner, offering invaluable support in shaping business strategies and conducting market research across the entire drug value chain.

DelveInsight's primary conduit for delivering intelligent information to professionals in both the business and healthcare sectors is through its meticulously crafted analytical and strategic reports. Presently, DelveInsight boasts a diverse portfolio encompassing over 3,000 Marketed and Pipeline Reports. These reports are thoughtfully categorized based on parameters such as indication, mechanism of actions, drugs, global API manufacturers, and specialized reports focusing on pivotal areas such as Onco-Immunology, Orphan Diseases, Biologics & Biosimilars, Gene Therapy, Stem Cells Therapy, and other emerging domains. This robust platform has become the go-to resource for numerous enterprises seeking to transform and redefine their business strategies.

DelveInsight's offerings extend beyond reports to encompass Consulting Projects and Competitive Intelligence services, catering to the multifaceted needs of its clientele. Moreover, the organization is dedicated to providing tailor-made research services that align with the specific interests and requirements of its clients. DelveInsight's commitment to excellence and innovation positions it as a trusted partner in the areas of business strategy and market research.

View recent articles by this publisher on our blog:
4 Blockbuster Drugs to Watch for Non-Small Lung Cancer (NSCLC)
The Power of Digital Therapeutics in Mental Health
Anti-VEGF Therapies: Forever Market Rulers of Wet-AMD Treatment?
Additional articles from this publisher

...Show More ...Show Less

8,774 Reports from DelveInsight

Sort by:

CRISPR Therapies- Pipeline Insight, 2024

Dec 01, 2024 | Published by: DelveInsight | USD 2,000

CRISPR Therapies- Pipeline Insight, 2024 DelveInsight’s, “CRISPR Therapies- Pipeline Insight, 2024” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage ... Read More
Dengue Fever- Pipeline Insight, 2024

Dec 01, 2024 | Published by: DelveInsight | USD 1,500

Dengue Fever- Pipeline Insight, 2024 DelveInsight’s, “Dengue Fever- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Dengue Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. I ... Read More
Osteoporosis - Pipeline Insight, 2024

Dec 01, 2024 | Published by: DelveInsight | USD 2,000

Osteoporosis - Pipeline Insight, 2024 DelveInsight’s, “Osteoporosis - Pipeline Insight, 2024” report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Osteoporosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. ... Read More
Epilepsy - Pipeline Insight, 2024

Dec 01, 2024 | Published by: DelveInsight | USD 3,000

Epilepsy - Pipeline Insight, 2024 DelveInsight’s, “Epilepsy - Pipeline Insight, 2024” report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in Epilepsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also cov ... Read More
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease- Pipeline Insight, 2024

Dec 01, 2024 | Published by: DelveInsight | USD 1,500

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease- Pipeline Insight, 2024 DelveInsight’s, “Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Alpha-1 Antitrypsin Deficiency (A1ATD) Live ... Read More
Hypersomnia - Pipeline Insight, 2024

Dec 01, 2024 | Published by: DelveInsight | USD 1,500

Hypersomnia - Pipeline Insight, 2024 DelveInsight’s, “Hypersomnia - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Hypersomnia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It ... Read More
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)- Pipeline Insight, 2024

Dec 01, 2024 | Published by: DelveInsight | USD 1,250

Acute Bacterial Skin and Skin Structure Infections (ABSSSI)- Pipeline Insight, 2024 DelveInsight’s, “Acute Bacterial Skin and Skin Structure Infections (ABSSSI)- Pipeline Insight, 2024” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Acute Bacterial Skin and Skin S ... Read More
Poly (ADP-ribose) Polymerase Inhibitors - Pipeline Insight, 2024

Dec 01, 2024 | Published by: DelveInsight | USD 2,000

Poly (ADP-ribose) Polymerase Inhibitors - Pipeline Insight, 2024 DelveInsight’s, “Poly (ADP-ribose) Polymerase Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Poly (ADP-ribose) Polymerase Inhibitors pipeline landscape. It cov ... Read More
Bronchopulmonary Dysplasia - Pipeline Insight, 2024

Dec 01, 2024 | Published by: DelveInsight | USD 1,500

Bronchopulmonary Dysplasia - Pipeline Insight, 2024 DelveInsight’s, “Bronchopulmonary Dysplasia - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Bronchopulmonary Dysplasia pipeline landscape. It covers the pipeline drug profiles, includin ... Read More
Metastatic Castration-Resistant Prostate Cancer- Pipeline Insight, 2024

Dec 01, 2024 | Published by: DelveInsight | USD 3,000

Metastatic Castration-Resistant Prostate Cancer- Pipeline Insight, 2024 DelveInsight’s, “Metastatic Castration-Resistant Prostate Cancer- Pipeline Insight, 2024” report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Metastatic Castration-Resistant Prostate Cancer pipel ... Read More
PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2024

Dec 01, 2024 | Published by: DelveInsight | USD 2,000

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2024 DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2024” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline ... Read More
Autoimmune Psychosis – Market Insight, Epidemiology, and Market Forecast – 2034

Nov 11, 2024 | Published by: DelveInsight | USD 7,950

Autoimmune Psychosis – Market Insight, Epidemiology, and Market Forecast – 2034 DelveInsight’s “Autoimmune Psychosis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Autoimmune Psychosis, historical and forecasted epidemiology as well as the ... Read More
FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034

Nov 01, 2024 | Published by: DelveInsight | USD 7,950

FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 Key Highlights In 2023, the total market size of CHF was around USD 8,000 million in the 7MM—the increasing prevalence of the disease is expected to fuel the market during 2020–2034. The prevalence of heart ... Read More
Pemphigus Vulgaris (PV) - Market Insight, Epidemiology And Market Forecast - 2034

Nov 01, 2024 | Published by: DelveInsight | USD 7,950

Pemphigus Vulgaris (PV) - Market Insight, Epidemiology And Market Forecast - 2034 Key Highlights In 2023, there were an estimated 42 million prevalent cases of MASH in the 7MM. Out of these, a total of ~15 million cases were diagnosed, and this number is projected to increase by the end of 2034 in t ... Read More
Idiopathic Inflammatory Myositis – Market Insights, Epidemiology, and Market Forecast – 2034

Nov 01, 2024 | Published by: DelveInsight | USD 7,950

Idiopathic Inflammatory Myositis – Market Insights, Epidemiology, and Market Forecast – 2034 Key Highlights According to the National Organization for Rare Disorders (2023), pemphigus vulgaris (PV) is a severe, rare autoimmune disorder marked by painful blisters and erosions on the skin and mucous m ... Read More
Yellow Fever- Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 1,250

Yellow Fever- Pipeline Insight, 2024 DelveInsight’s, “Yellow Fever- Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Yellow Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It ... Read More
Complement Inhibitors - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 2,500

Complement Inhibitors - Pipeline Insight, 2024 DelveInsight’s, “Complement Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Complement Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and ... Read More
Pompe Disease - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 2,000

Pompe Disease - Pipeline Insight, 2024 DelveInsight’s, “Pompe Disease - Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Pompe Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage produc ... Read More
Pre-Eclampsia - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 1,250

Pre-Eclampsia - Pipeline Insight, 2024 DelveInsight’s, “Pre-Eclampsia - Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pre-Eclampsia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products ... Read More
Gout - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 2,000

Gout - Pipeline Insight, 2024 DelveInsight’s, “Gout - Pipeline Insight, 2024,” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Gout pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the the ... Read More
Schizophrenia - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 2,500

Schizophrenia - Pipeline Insight, 2024 DelveInsight’s, “Schizophrenia- Pipeline Insight, 2024” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage product ... Read More
Diabetic Peripheral Neuropathy- Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 2,000

Diabetic Peripheral Neuropathy- Pipeline Insight, 2024 DelveInsight’s, “Diabetic Peripheral Neuropathy- Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Diabetic Peripheral Neuropathy pipeline landscape. It covers the pipeline drug profiles ... Read More
Peripheral Arterial Disease (PAD)- Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 2,000

Peripheral Arterial Disease (PAD)- Pipeline Insight, 2024 DelveInsight’s, “Peripheral Arterial Disease (PAD)- Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Peripheral Arterial Disease (PAD) pipeline landscape. It covers the pipeline drug ... Read More
Graves’ Disease - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 1,500

Graves’ Disease - Pipeline Insight, 2024 DelveInsight’s, “Graves’ Disease- Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Graves’ Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage pr ... Read More
HSV-1 Keratitis- Competitive landscape, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 1,250

HSV-1 Keratitis- Competitive landscape, 2024 DelveInsight’s, “ HSV-1 Keratitis- Competitive landscape, 2024,” report provides comprehensive insights about 5+ companies and 5 drugs in HSV-1 Keratitis Competitive landscape. It covers the therapeutics assessment by product type, stage, route of admini ... Read More